• Mice expressing RGS-insensitive Gαi2 have an antidepressant-like phenotype.
Introduction
Although selective serotonin reuptake inhibitors (SSRIs) are widely used in psychiatric treatments this class of drugs suffers from serious drawbacks including limited clinical efficacy and a long delay between the initiation of treatment and the onset of therapeutic effects. This lag period is thought to be caused by the need to activate and subsequently desensitize serotonin 1A (5-HT1A) autoreceptors located predominantly in the raphe nucleus (Hjorth et al., 2000) . However, a substantial body of research has identified 5-HT1A receptors (5-HT1ARs) on postsynaptic sites, so called heteroreceptors, in the frontal cortex and hippocampus as potential mediators of the beneficial effects of serotonergic antidepressants (e.g. Celada et al., 2013) . The involvement of 5-HT1ARs in both the therapeutic and negative effects of SSRIs https://doi.org/10.1016/j.neuropharm.2018.09.002 Received 3 May 2018; Received in revised form 31 August 2018; Accepted 2 September 2018 has hindered the development of new antidepressant therapies which maintain the beneficial effects of SSRIs while avoiding their drawbacks.
The 5-HT1AR is a typical 7-transmembrane domain G-protein-coupled receptor (GPCR) with high expression throughout the brain (Ito et al., 1999) . The 5-HT1AR couples to heterotrimeric G-proteins comprised of Gα i/o and βγ subunits and as such its signaling is moderated by the regulators of G-protein signaling (RGS) proteins (Beyer et al., 2004; Ghavami et al., 2004; Wang et al., 2014) . RGS proteins are a large family of intracellular proteins that regulate G-protein function by directly interacting with and inactivating heterotrimeric G-proteins (Berman et al., 1996) . RGS proteins have GTPase accelerating (GAP) activity which promotes the hydrolysis of active Gα-GTP to form inactive Gα-GDP. This allows for reformation of the inactive Gαβγ heterotrimer thus halting downstream signaling activity of both the Gα and βγ subunits.
The high degree of functional redundancy between individual RGS proteins has provided a significant hurdle to understanding the specific function of individual RGS proteins (Dong et al., 2000; Doupnik et al., 2001; Chen et al., 2010) . In order to overcome this issue a series of RGS insensitive (RGSi) Gα protein variants have been developed (Lan et al., 1998; Huang et al., 2006) . These mutant Gα proteins have a single base mutation (Gly to Ser) at the conserved site where RGS proteins interact with their cognate Gα subunit (Tesmer et al., 1997) . For Gα i2 this is Gly184. The mutation prevents interaction of the Gα protein with all RGS proteins while maintaining normal enzyme kinetics and interactions with receptor and downstream effectors (Fu et al., 2004; Clark et al., 2003) and so provides the opportunity to determine the effect of removing RGS control of a specific Gα protein.
Homozygous mice expressing the RGSi Gα i2 protein (Gα i2 GS/GS ) display a baseline antidepressant-like phenotype which is fully reversible by 5-HT1AR antagonist treatment (Talbot et al., 2010) , suggesting an important role for Gα i2 and RGS proteins downstream of the 5-HT1AR. However, hypothermia, an action traditionally associated with 5-HT1A autoreceptor activation in the raphe nucleus, is not affected by the mutation, indicating that postsynaptic 5-HT1A heteroreceptors are the important mediators of the antidepressant-like behavior in the Gα i2 GS/GS mice. Identifying the brain locus responsible for the antidepressant-like phenotype in these mice would be an important step forward and allow us to study individual RGS proteins expressed in regions of the brain that regulate Gα i2 downstream of the 5-HT1AR. The hippocampus and frontal cortex of the Gα i2 GS/GS mice have increased levels of the Ser-9 phosphorylated version of glycogen synthase kinase-3β (GSK3β) that is reversed by treatment with the 5-HT1AR antagonist WAY100635 (Talbot et al., 2010) . GSK3β is a neurogenic factor that is phosphorylated by antidepressant drug treatment and may contribute to their therapeutic effects (Malberg et al., 2000; Tsai et al., 2008) . The increased levels of phospho-GSK3β in the Gα i2 GS/GS mice suggest the hippocampus and/or frontal cortex as potential critical sites of their 5-HT1AR dependent antidepressant-like behavior.
To test this hypothesis, we targeted the hippocampus of wild type and Gα i2 GS/GS mice and measured antidepressant-like behavior using the tail suspension test (TST). We find that hippocampal microinjection of a 5-HT1AR antagonist fully reverses the Gα i2 GS/GS antidepressant-like phenotype, while hippocampal injection of a 5-HT1AR agonist to wild type animals produces effects consistent with the RGSi Gα i2 GS/GS behavioral phenotype. We also show that 5-HT1AR agonists have an enhanced inhibitory effect on the intrinsic excitability of CA1 hippocampal neurons from heterozygous Gα i2 +/GS mice. Finally, we demonstrate that inhibiting an RGS protein with high hippocampal expression can produce an antidepressant-like effect in female wild type mice. No changes in 5-HT1ARs in the hippocampus of the RGSi Gα i2 mice compared to their wild type littermates were observed.
Materials and methods

Drugs
eN-2-pyridinylcyclohexanecarboxamide maleate) were purchased from Sigma-Aldrich (St Louis, MO). CCG-203769 was synthesized as previously described (Blazer et al., 2015 ) and homozygous (Gα i2 GS/GS ) RGSi Gα i2 knock-in mice were derived from heterozygous breeding as described previously . Animals were backcrossed onto the C57BL/6J background strain for four generations. Wild type (+/+) and heterozygous (+/GS) RGSi Gα o knock-in mice were generated as described previously on a 129S1/SvIMJ background (Fu et al., 2004; Fu et al., 2006; Huang et al., 2006; Goldenstein et al., 2009 (Council, 2011) .
Intra-hippocampal infusions
Mice were anesthetized with a combination of Ketamine (100 mg/ kg i.p.) and Xylazine (10 mg/kg i.p.). Carprofen (5 mg/kg s.c.) was administered before and every 24 h following surgery for 48 h as an analgesic. Mice were placed into the stereotax (Kopf Instruments Model 902 Dual Small Animal Stereotaxic Instrument) and a midline incision made over the top of the skull. Bregma and lambda were located and marked to determine implant position. Bilateral implant coordinates were 1.5 mm posterior, 1.0 mm ventral and 1.0 mm distal from the midline on both sides. Bilateral guide cannulae were custom ordered from Plastics One Inc. with a center-to-center distance of 2.0 mm between each cannula arm and with 2.0 mm cannula arm length. In order to prevent blockage within the guide cannula a bilateral dummy cannula was kept in the guide cannula at all times following surgery except during intra-hippocampal infusions. Animals were allowed to recover for at least seven days following surgery before any experimental testing took place. Any animals that showed signs of distress during this period were removed from the experiment and euthanized. Following experimental testing, a solution containing Fast Green FCF dye was infused through the cannula. Brains were then dissected and rapidly frozen before sectioning. When staining indicated a misplaced cannula, data from this animal was excluded from the experiment.
Immediately before infusion animals were placed in a drop jar containing isoflurane and breathing was monitored until rate reached approximately one breath per second. A bilateral injection cannula attached by flexible plastic tubing to two Hamilton syringes (Hamilton #86274 syringe) was then inserted through the guide cannula. A 500 nl infusion was then delivered to each side at a rate of 250 nl per second using a syringe pump (NE-300 pump, New Era Pump Systems Inc.). Following infusion, the injection cannula remained in place for a further 2 min to prevent backflow away from the infusion site. Drugs were administered 30 min before testing unless otherwise indicated. For experiments involving repeated intra-hippocampal infusions this process was repeated once every 24 h for three days, and experimentation occurred 30 min after the final infusion.
Tail suspension test
A piece of adhesive tape was affixed to the distal end of the mouse' tail and attached to a metal bar elevated 30 cm above the table surface (Steru et al., 1985) . Behavior was video-recorded for 6 min and later scored for immobility time. Immobility was defined as any period without continuous movement. Isolated head movements, and swinging without other movement were also defined as immobile.
Hypothermia
Mice were moved from group housing to individual cages 2 h before testing with free access to food and water. Baseline temperatures were taken once every 10 min for 30 min before experimental treatment. Temperatures were determined using a Tcat 2df controller rectal thermometer (Physitemp Clifton, NJ) inserted to a 20 mm probe depth. All animals in this study received both an i.p. and an intra-hippocampal injection, with the i.p. injection immediately following the third baseline measurement and intra-hippocampal infusion immediately following i.p. injection. Drug effects were determined 10, 20 and 30 min after injection.
Ex-vivo hippocampal cell recordings
Whole cell patch clamp recordings of hippocampal CA1 neurons were made from wild type and heterozygous RGSi Gα i2 knock-in mice (5-8 weeks of age). Mice were anesthetized with isofluorane and brains were rapidly removed and placed in ice-cold oxygenated (95% O 2 -5% CO 2 ) artificial cerebrospinal fluid (aCSF) containing (in mM): 200 sucrose, 25 NaHCO 3 , 12.5 glucose, 1.25 NaH 2 PO 4 , 3.5 KCl, 1 L-ascorbic acid, 0.5 CaCl 2 , 3 MgCl 2 , 305 mOsm, pH 7.4. Coronal slices (300 μm) containing the hippocampus were made using a Leica VT1200 vibratory microtome (Leica Biosystems, Buffalo Grove, IL, USA) and allowed to rest in oxygenated aCSF for at least 40 min before recording. For the recording aCSF, CaCl 2 was increased to 2.5 mM and MgCl 2 was decreased to 1 mM. Patch pipettes were pulled from 1.5 mm borosilicate glass capillaries (WPI, Sarasota, FL) to a resistance of 3-7 MΩ with a horizontal puller (Model P97, Sutter Instruments, Novato, CA, USA) and filled with a solution containing (in mM): 130 K-methanesulfonate, 10 KCl, 0.4 EGTA, 2 MgCl 2 , 2 Mg 2+ -ATP, 0.25 Na
3+
-GTP, and 10 HEPES, pH 7.3, 285 mOsm when performing current clamp experiments. CA1 hippocampal neurons were identified based on their response to current injection (−200 to 140 pA, 10 pA increments, 500 ms). Neuronal excitability was determined by measuring the number of action potentials elicited by each depolarizing current injection. Input resistance (IR) was determined by the change in voltage from 0 pA to −170 pA current injections. Rheobase is defined as the minimum amount of current injection to elicit an action potential.
Hippocampal membrane preparation
Mice were sacrificed by cervical dislocation followed by decapitation and the brain was removed. The hippocampus was then immediately dissected. Hippocampi from 6 to 8 mice matched for age, gender and genotype were pooled to obtain sufficient tissue, homogenized in ice cold 50 mM Tri-HCl buffer pH 7.4 and membrane homogenates prepared as described previously (Lester and Traynor, 2006) . Protein concentration was determined using a BCA assay kit (Thermo Scientific, Rockford, IL).
5-HT1A receptor binding
Hippocampal membrane homogenates (100 μg protein/well) were incubated in 50 mM pH 7.4 Tris-HCl buffer with eight concentrations of the 5HT1A receptor ligand [ 3 H] 8-OH-DPAT ranging in concentration from 0.16 nM to 20 nM. Non-specific binding was determined using 10 μM WAY-100635. The assay was incubated for 60 min at room temperature before filtration through a Whatman GF/C filters using a MLR-24 Brandel harvester. Bound radioactivity was then determined by scintillation counting with a Wallac 1450 Microbeta counter (Perkin Elmer). Each condition was performed in triplicate and independently replicated three times.
Western blotting
Hippocampal homogenates containing 20 μg of protein were mixed with sample buffer (63 mM Tris-HCl, pH 6.8, with 2% sodium dodecyl sulfate (SDS), 10% glycerol, 0.008% bromophenol blue, and 50 mM dithiothreitol) and 50 mM pH 7.4 Tris-HCl buffer to a total volume of 25 μl. Samples were then separated by SDS-PAGE using polyacrylamide gels and transferred to a nitrocellulose membrane (Pierce). Membranes were probed with primary antibodies against each Gα subtype (Gα o , Gα i1 , Gα i2 , Gα i3 , Gβγ (1-6) and RGS19; Santa Cruz Biotechnology). Each membrane was also stripped and re-probed for α-tubulin or β-actin as loading control (Sigma-Aldrich). Horseradish peroxidase-conjugated anti-mouse and anti-rabbit secondary antibodies were used for chemiluminescent detection in combination with SuperSignal™ West Pico Chemiluminescent Substrate (ThermoFisher Scientific). Signal intensity was determined using Image J software (http://rsbweb.nih.gov/ ij/index.html).
Statistical analysis
GraphPad Prism 7.0 (GraphPad; La Jolla, CA) was used to analyze all reported data. Two-way analysis of variance (2-way ANOVA) was used to analyze data involving two independent drug treatments as well as data involving a genetic variable and a drug treatment. Prior to all parametric comparisons, normality of the data distribution was evaluated using the Shapiro-Wilk normality test. Post-hoc tests were Tukey's or Sidak's multiple comparisons. Experiments involving only two conditions were analyzed by Student's t-test. Threshold for significance was p < 0.05 for all experiments. In saturation binding experiments affinity (Kd) and maximal binding (Bmax) were obtained using a one-site saturation binding curve with Hill slope set to 1 as described previously (Lamberts et al., 2013) .
Results
Effects of intra-hippocampal WAY100635 on tail suspension test responses in wild type and Gα i2 GS/GS mice
Homozygous Gα i2 GS/GS knock-in mice given saline bilaterally into the hippocampus exhibited less immobility (92.7 ± 27.5 s) in the TST than their wild type littermates (183 ± 7.3 s; Fig. 1 ), confirming that the intra-hippocampal microinjection procedure does not disrupt the previously described antidepressant-like phenotype in these mice. Bilateral intra-hippocampal administration of WAY100635 (3 μg each side) fully reversed the reduction in immobility back to levels seen in wild type littermates (186 ± 13.3 s). WAY100635 similarly administered to wild type littermates had no effect (186 ± 11.2 s; Fig. 1 ). Twoway ANOVA revealed a significant interaction (WAY100635 × genotype, F(1,22) = 7.34, p = 0.013) and significant main effects of genotype (F(1,22) = 9.5, P = 0.006) and WAY100635 (F(1,22) = 7.05, p = 0.01).
Effects of intra-hippocampal 8-OH-DPAT on tail suspension test immobility and hypothermia in wild type mice
The reversal of the Gα i2 GS/GS behavioral phenotype by intra-hippocampal WAY100635 suggests the hippocampus as a primary site of the increased 5-HT1AR signaling and thus of the antidepressant-like phenotype. Therefore, we sought to test if we could mimic this behavioral phenotype by administration of the 5-HT1AR agonist 8-OH-DPAT directly into the hippocampus of wild type Gα i2 +/+ mice. Intra-hippocampal 8-OH-DPAT (3 μg) bilaterally into the hippocampus of Gα i2 +/+ mice resulted in an immobility time of 51.3 ± 11.5 s. This action of 8-OH-DPAT was attenuated by systemic (s.c) administration of 0.1 mg/kg WAY100635 (Fig. 2) , giving an immobility time of 133 ± 20.6 s (n = 7). This dose of WAY100635 did not affect the behavior of animals given an intra-hippocampal saline infusion ( Activation of 5-HT1ARs in the raphe nuclei modulates body temperature (Hillegaart, 1991) . Doses of 8-OH-DPAT that produce an antidepressant-like effect when administered peripherally (1 mg/kg and 10 mg/kg, i.p., Talbot et al., 2010) produced a lasting hypothermic effect in Gα i2 +/+ animals (Fig. 2B) . In contrast doses of 8-OH-DPAT that produce an antidepressant-like effect in the TST when administered into the hippocampus (3μg/side) did not affect body temperature (Fig. 2B ). There was a significant interaction between time and treatment as determined by two-way ANOVA (F(9,84) = 5.01, p = 0.0001), and significant main effects of time (F(3,84) = 20.2, p = 0.0001 and treatment (F(3,84) = 39.9, p = 0.0001).
Effect of 8-OH-DPAT on excitability of CA1 hippocampal neurons
Both 5-HT1AR and Gα i2 are expressed in mouse hippocampus (see Fig. 5 ), in agreement with published results (Laporte et al., 1994; Marazziti et al., 1994 ; Allen Brain Atlas). Based on the above results and our previous findings (Talbot et al., 2010) we predicted that the decreased immobility in the Gα i2 GS/GS mice is due to increased activation of hippocampal 5-HT1ARs coupled to Gα i2 . 5-HT1AR activation alters potassium currents and hyperpolarization-activated currents to regulate cell excitability (Ko et al., 2016; Andrade and Nicoll, 1987; Colino and Halliwell, 1987; Oleskevich, 1995) . Therefore, to test for increased 5-HT1AR activity, we compared the effect of 8-OH-DPAT between heterozygous (Gα i2 GS/+ ) and Gα i2 +/+ littermates on the excitability of CA1 hippocampal neurons (Czyrak et al., 2002) . Heterozygous mice were used because the homozygous animals show a maximal antidepressant-like effect in the tail suspension test (Talbot et al., 2010) and we have previously shown that this 5-HT1AR agonist has increased potency in the heterozygotes (Talbot et al., 2010) . We recorded the responses of CA1 hippocampal neurons to current injection from minus 200 pA to plus 140 pA at 10 pA intervals before and after 5 μM 8-OH-DPAT application in Gα i2 +/+ and Gα i2 GS/+ littermates (Gα i2 GS/ GS ). Antidepressant-like behavior was measured using the TST. Intra-hippocampal WAY100635 (3μg/side) reversed the baseline activity in the RGSi Gα i2 expressing mice (GS/GS) with no action in wild-type (WT) littermates. Each column depicts the mean immobility score ± SEM of 6-7 mice. **p < 0.01 compared to saline treated wild type mice; ##p < 0.01 compared to saline treated RGSi Gα i2 expressing mice.
Fig. 2. Effect of intrahippocampal 8-OH-DPAT administration in wild type mice. (A) Intra-hippocampal (intra-HPC) administration of 8-OH-DPAT (DPAT)
produces an antidepressant-like effect in the TST in wild type mice that is reversed by WAY100635 (0.1 mg/kg s.c.). Each column depicts the mean immobility score ± SEM of 6 mice. ***p < 0.001); between saline and 8-OH-DPAT; ##p < 0.01 between s.c. WAY100635 and s.c. saline. (B) Intra-hippocampal 8-OH-DPAT (3 μg/side) does not produce a hypothermic effect at doses capable of producing antidepressant-like effects. Each line represents the mean temperature ± SEM recorded from 6 to 7 mice at each time; **, *** and **** (p < 0.01, p < 0.001 and p < 0.0001 respectively) indicate a difference between 8-OH-DPAT and vehicle treated animals. Animals receiving 3μg/ side 8-OH-DPAT by intra-hippocampal infusion were not significantly different from vehicle treated animals at any time point.
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In addition, bath application of 8-OH-DPAT produced a significant decrease in resting membrane potential in cells from the Gα i2 GS/+ mice (−71.7 ± 2.0 mV to −76.4 ± 2.1 mV; t(8) = 6.9, p < 0.001), but not their Gα i2 +/+ littermates (−74.2 ± 1.1 to −75.6 ± 2.2; t Overall, the results demonstrate that 5 μM 8-OH-DPAT application caused a decrease in membrane excitability in hippocampal CA1 neurons only from Gα i2 GS/+ mice, but this concentration was ineffective in neurons from Gα i2 +/+ littermates, showing increased activity of the 5-HT1AR agonist in the absence of RGS activity.
Effect of the RGS19/RGS4 inhibitor, CCG-203769, on tail suspension test responses
We have previously demonstrated that RGS19 acts as a negative modulator of 5-HT1AR signaling in mouse hippocampal neurons in vitro (Wang et al., 2014) . To examine if this is a critical component of the 5-HT1AR signaling pathway in the hippocampus in vivo, we used the RGS19/RGS4 inhibitor CCG-203769 (Blazer et al., 2015) . A single, acute intra-hippocampal administration of CCG-203769 (3 μg/side) produced a non-significant trend to antidepressant-like behavior (data not shown). CCG-203769 is an irreversible inhibitor of RGS19 and RGS4 but may not be inactivating a sufficient level of the RGS protein after a single administration. Therefore, to further inhibit RGS activity we gave three infusions separated by 24 h. Female, but not male, wild type mice showed a reduction in immobility compared to vehicle treated controls. Two-way ANOVA revealed a significant sex × treatment interaction (F(1,21) = 6.4, p = 0.02) and significant main effects for sex (F(1,21) = 15.7, p = 0.0007) and treatment (F(1,21) = 4.4, p = 0.05; Fig. 4A ). There was no significant difference in the potency of 8-OH-DPAT in the TST between male and female wild type mice (Fig. 4B) . Hippocampal homogenates from male and female wild type mice did not significantly differ in RGS19 protein expression as determined by western blot (Fig. 4C) , although there was a trend to less RGS19 in the female mice.
Hippocampal [ 3 H] 8-OH-DPAT binding and G-protein expression in
RGSi Gα i2 knock-in mice
In order to determine whether the electrophysiological and behavioral changes observed in the RGSi Gα i2 mice could be explained by compensatory changes in 5-HT1AR expression, we characterized 5-HT1AR ligand binding in the mouse hippocampus. Saturation binding with [
3 H] 8-OH-DPAT was performed in hippocampal membrane homogenates from wild type and heterozygous (+/GS) RGSi Gα i2 mice (Fig. 5A ). Neither the maximal receptor expression (Bmax) nor the affinity (Kd) of [ 3 H] 8-OH-DPAT binding were significantly different between RGSi Gα i2 and wild type mice (Table 1) , indicating no large changes between the genotypes. However, variability in the data could have obscured small differences. Hippocampal homogenates from wild type and RGSi Gα i2 knock-in mice were assayed by western blotting for heterotrimeric G-proteins subunits using primary antibodies against Gα o , Gα i1 , Gα i2 , Gα i3 and Gβγ(1-6); Fig. 5B ). There was a decrease in the level of Gαi 1 between wild type and the homozygotes and a trend to a decrease in Gαi 2 .
Effects of peripheral WAY100635 on tail suspension test responses in heterozygous RGSi Gα o knock-in mice
Gα i2 appears to play a critical role in regulating antidepressant-like behavior via the 5-HT1AR as RGSi Gα i2 knock-in mice have an antidepressant-like phenotype, while Gα i2 knockout mice exhibit pro-depressant behaviors (Talbot et al., 2010) . However, 5-HT1ARs also couple to Gα o especially in the frontal cortex and hippocampus (la Cour et al., 2006) . To examine whether loss of RGS control of Gα o similarly affected behavior, we studied mice expressing RGSi Gα o proteins (Gα o GS/GS ; Fu et al., 2006; Lamberts et al., 2013) . The homozygous knock-in mice are not viable but heterozygote Gα o GS/+ mice showed a reduction in immobility compared to wild type littermates in the TST (Fig. 6) . However, unlike the RGS Gα i2 mice, systemic (s.c.) injection of 0.1 mg/ N.B. Senese et al. Neuropharmacology 141 (2018) 296-304 kg WAY100635 did not reverse the behavioral phenotype (Fig. 6) . Twoway ANOVA disclosed a main effect of genotype (F(1,30) = 16.2, p = 0.0004) but no genotype x WAY100635 interaction (F (1,30) = 0.086, p = 0.8) or main effect of WAY100635 (F (1,30) = 0.01, p = 0.9) showing that the low levels of immobility in the Gαo GS/+ mice are not due to activity in the 5-HT1A receptor system.
Discussion
The current results show that the antidepressant-like behavioral phenotype observed in the TST in mice expressing an RGS-insensitive variant of Gα i2 (Gα i2 GS/GS ) was fully reversed by administration of the 5-HT1AR antagonist WAY100635 locally to the hippocampus, suggesting enhanced signaling of endogenous serotonin at this site. The behavioral phenotype observed in the RGSi Gα i2 mice was accompanied by increased activity of the agonist 8-OH-DPAT on hippocampal slices, such that a concentration of 8-OH-DPAT that was ineffective in slices from wild-type mice caused hyperpolarization in slices from the mutant mice. These data suggest that promoting signaling through the 5-HT1AR/Gα i2 complex in the hippocampus selectively enhances the antidepressant-like effects of 5-HT1AR agonism and that hippocampal 5-HT1ARs appear to be necessary and sufficient to explain the antidepressant-like behavior in mice expressing RGSi Gα i2 protein. These conclusions do not appear to be confounded by developmental changes caused by the constitutive knock-in of an RGS-insensitive Gα i2. There were no changes in hippocampal 5-HT1ARs, although there was a paradoxical reduction in the level of Gα i1 and a trend to decreased level of Gα i2 in the homozygote mutant mice compared to their wild-type littermates. This likely represents a compensatory response in an attempt to reduce the increased activity of 5-HT1AR signaling due to the RGSi mutant of the Gα i2 . We have observed a similar compensatory decrease in the level of Gα o in mice expressing RGSi Gαo (Lamberts et al., 2013) . Moreover, the mutant phenotype was mimicked by direct hippocampal administration of the 5-HT1AR agonist 8-OH-DPAT to mice expressing wild type Gα i2 (Gα i2 +/+ ), that was in turn fully blocked by systemic WAY100635, and by hippocampal administration of an RGS19/4 inhibitor, although only in female mice. While it remains difficult to develop drugs that target a specific GPCR bound to a particular G-protein subunit, targeting RGS proteins may provide an additional level of selectivity. RGS family members 2, 7, 8, 10, 14 and 19 are expressed in the hippocampus at high levels, while 4, 5, 11 and 13 are expressed only moderately, and 3, 6, 9 and 16 are expressed at very low levels or are absent (Gold et al., 1997; Grafstein-Dunn et al., 2001) . Of these RGS proteins, RGS19 regulates 5-HT1AR function in isolated hippocampal neurons (Wang et al., 2014) . These properties make RGS19 an attractive target to selectively enhance hippocampal 5-HT1AR function for potential antidepressant effects while avoiding the drawbacks of activating all 5-HT1ARs expressed in the CNS. Due to the lack of a highly selective RGS19 small molecule inhibitor we tested the effects of CCG-203769, a RGS19/RGS4 dual inhibitor (Blazer et al., 2015) . CCG-203769 forms a disulfide bridge with these RGS proteins leading to permanent inactivation (Turner et al., 2012) . Repeated (3-day) administration of CCG-203769 bilaterally into the hippocampus was necessary to produce an anti- No sex difference is seen in the sensitivity to 8-OH-DPAT as determined by the mean immobility score ± SEM of 6-7 mice. (C) Hippocampal RGS19 expression was determined by western blot, normalized to α-Tubulin expression and the ratio of G-protein/α-Tubulin expression was averaged across three independent experiments ± SEM. No significant difference was seen in RGS19 signal intensity between male and female animals, unpaired t-test). Blot shows RGS19 bands detected at ∼25 kDa for hippocampal homogenates from 3 different female mice (lanes 1-3) and 3 different male mice (lanes 4-6).
depressant-like effect, but surprisingly this was only seen in female mice. This sex difference was not explained by differences in hippocampal RGS19 protein expression as levels were similar between male and female mice. In addition, there was no sex difference in the antidepressant-like effects of 8-OH-DPAT suggesting that a differential response to 5-HT1AR activation is not the primary cause. The disparity may be due to a lower potency of CCG-203769 in males compared to females rather than an all-or-none difference or to a greater sensitivity of male mice to motor suppression by CCG-203769 since intra-hippocampal infusion of a single dose of 10 μg/side CCG-203769 produced motor suppression and catatonia in the mice. This may be an off-target effect of high doses of CCG-203769 since peripheral administration of this inhibitor has been shown to reverse raclopride-induced suppression of movement (Blazer et al., 2015) .
Although RGS19 inhibition is a promising candidate for the antidepressant-like phenotype behavior in the Gα i2 GS/GS mice and for antidepressant-like effect of CCG-203769 in female wild type mice, inhibition of other RGS proteins may play a role. Out of all the RGS proteins tested with CCG-203769, only RGS4 is inhibited more potently than RGS19 (Blazer et al., 2015) . Overexpressed RGS4 inhibits 5-HT1AR signaling in the raphe nuclei (Beyer et al., 2004) , but RGS4 knockout mice show no change in baseline antidepressant-like behavior compared to their wild-type controls and show a decreased response to a selective serotonin reuptake inhibitor in the forced swim test (Stratinaki et al., 2013) suggesting that RGS4 is a positive modulator. Thus RGS4 inhibition likely cannot explain the antidepressant-like effects seen in the Gα i2 GS/GS mice or after CCG-203769 treatment. In contrast, RGS6 knockout (RGS6
) mice do show a 5-HT1AR-mediated baseline antidepressant-like phenotype (Stewart et al., 2014) . Whereas this behavioral response is consistent with antidepressant-like effects seen in Gα i2 GS/GS mice there is no evidence that CCG-203769 interacts with RGS6. RGS6 is a member of the R7 family of RGS proteins that includes RGS6, 7, 9 and 11 (Hollinger and Hepler, 2002) . CCG-203769 has over 1000-fold selectivity for RGS19 compared to other R7 RGS family members (Blazer et al., 2015) and RGS6 lacks an available cysteine residue to form a covalent interaction with CCG-203769. In point represents the mean specific binding ± SEM from three independent experiments (best fit lines for Kd and Bmax calculation were determined using a one-site saturation binding fit with Hill slopes set to 1 and fitted to mean results averaged across experiments; Bmax and Kd compared between WT and +/GS using unpaired t-test, showed no significant differences. (B) G-protein was measured by western blot and signal intensity was normalized to actin expression; mean G-protein/actin expression ± SEM was compared for hippocampi from three animals at each G-protein subunit. *p < 0.05, 1-Way ANOVA with Tukey's posthoc test. (C) Western blots of G proteins in hippocampal homogenates from mouse RGSi Gαi 2 genotypes. addition, the increased phospho-GSK3β levels seen in the Gα i2 GS/GS mice (Talbot et al., 2010) are not seen in the RGS6 −/− mice which instead show an increase in phospho-CREB (Stewart et al., 2014) . Thus, the mechanisms underlying the 5-HT1AR-mediated phenotype in the RGS6 −/− and Gαi2 GS/GS mice appear to be different.
The above discussion suggests that the complex of 5-HT1AR/Gα i2 with a specific RGS protein, possibly RGS19, might provide a suitable target for antidepressant drug therapy. Furthermore, this could offer an explanation for the selectivity of 5-HT1AR ligands, such as F15599, which show a preference for frontal cortex 5-HT1A heteroreceptors compared to raphe nuclei 5-HT1A autoreceptors (Newman-Tancredi et al., 2009) or ligands such as F13640 and F13714 with preference for 5-HT1A autoreceptors compared to other 5-HT1ARs . F15599 also stimulates 5-HT1ARs coupled to Gα i more potently and efficaciously than 5-HT1ARs coupled to Gα o , while serotonin shows no G-protein preference (Newman-Tancredi et al., 2009) , supporting the notion that a small molecule agonist can achieve selectivity.
Surprisingly we found that heterozygous mice expressing RGS-insensitive Gα o protein also exhibit an antidepressant-like phenotype. However, this behavioral phenotype was not reversed by the 5-HT1AR antagonist WAY100635, suggesting that the antidepressant-like behaviors displayed by the RGSi Gα i2 and RGSi Gα o mice are driven by distinct mechanisms. Studies in E. coli suggest that the 5-HT1AR couples more efficiently to Gα i2 than Gα o proteins (Bertin et al., 1992) . Although 5-HT1ARs do couple to other Gα proteins the close association between 5-HT1AR and Gα i2 is supported by a 5-HT1AR dependent antidepressant-like phenotype in the Gα i2 GS/GS mice and a pro-depressant phenotype in Gα i2 −/− mice (Talbot et al., 2010) .
When both the therapeutic and detrimental effects of a drug are mediated by the same molecular target developing new therapies is particularly challenging. The 5-HT1AR has long been recognized as one such target, where activation of autoreceptors on serotonergic cells is generally considered detrimental while activating heteroreceptors expressed on cells downstream of the serotonin neurons produces beneficial effects (Artigas, 1993; Blier and Abbott, 2001) . A considerable amount of effort has thus been spent on identifying strategies to block the 5-HT1A autoreceptors without affecting heteroreceptor activity, or conversely activating heteroreceptors without stimulating autoreceptor activity (Blier et al., 1993; Romero et al., 1996; Rabiner et al., 2000; Newman-Tancredi et al., 2009 ). The RGSi Gα i2 mutation appears to accomplish this as evidenced by a promotion of 5-HT1AR dependent antidepressant-like behaviors, but not hypothermic effects, although it is acknowledged that hypothermia is not a direct measure of raphe nuclei 5-HT1AR autoreceptor activity. Nonetheless, a therapeutic that can selectively enhance signaling through 5-HT1A/Gα i2 complexes, or alternatively selectively inhibit RGS proteins acting at Gα i2 , may dissociate the therapeutic and detrimental effects of 5-HT1A agonism with potential benefits for the neuropsychiatric treatment of depression.
